Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.45 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.45 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PYGB | P11216 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | OGA | O60502 | 2/20 | 0.38 |
| ▸ | HEXA | P06865 | 1/20 | 0.38 |
| ▸ | HEXB | P07686 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17358699 | 1.00 | L3MBTL1 (0.46) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL10147764 | 1.00 | L3MBTL1 (0.46) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL22011079 | 1.00 | L3MBTL1 (0.46) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL10147767 | 1.00 | L3MBTL1 (0.46) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL25140767 | 1.00 | L3MBTL1 (0.46) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL19430676 | 1.00 | L3MBTL1 (0.46) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL23591372 | 1.00 | L3MBTL1 (0.46) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL23266122 | 0.98 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL20713594 | 0.98 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL24825613 | 0.98 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11692004-B2 | Substituted pyrazole compound, preparation method therefor, pharmaceutical composition and medical use thereof | JIANGSU VANGUARD PHARMACEUTICAL CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-11382883-B2 | Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-07-12 | — | — | US | disclosed |
| US-10660911-B2 | Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-05-26 | — | — | US | disclosed |
| US-10632099-B2 | Non-aromatic difluoro analogues of resorcylic acid lactones | UNIVERSITY OF NORTH CAROLINA AT GREENSBORO (US) | 2020-04-28 | — | — | US | disclosed |
| US-10434085-B2 | Non-aromatic difluoro analogues of resorcylic acid lactones | UNIVERSITY OF NORTH CAROLINA AT GREENSBORO (US) | 2019-10-08 | — | — | US | disclosed |
| US-20180153854-A1 | NON-AROMATIC DIFLUORO ANALOGUES OF RESORCYLIC ACID LACTONES | NORTH CAROLINA AT GREENSBORO, UNIVERSITY OF | 2018-06-07 | — | — | US | disclosed |
| US-20180153854-A1 | NON-AROMATIC DIFLUORO ANALOGUES OF RESORCYLIC ACID LACTONES | NORTH CAROLINA AT GREENSBORO, UNIVERSITY OF | 2018-06-07 | — | — | US | disclosed |
| US-9718850-B2 | Triterpene saponins, methods of synthesis and uses thereof | MEMORIAL SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170172920-A1 | LIPOSOMES WITH GINSENOSIDE AS MEMBRANE MATERIAL AND PREPARATIONS AND USE THEREOF | Xiamen Ginposome Pharmaceutical Co., Ltd. (CN) | 2017-06-22 | — | — | US | disclosed |
| US-20170172920-A1 | LIPOSOMES WITH GINSENOSIDE AS MEMBRANE MATERIAL AND PREPARATIONS AND USE THEREOF | Xiamen Ginposome Pharmaceutical Co., Ltd. (CN) | 2017-06-22 | — | — | US | disclosed |
| US-9421269-B2 | Saponin nano micelle, preparing method, application and pharmaceutical composition thereof | FUJIAN SOUTH PHARMACEUTICAL CO., LTD. (CN) | 2016-08-23 | — | — | US | disclosed |
| US-20150297727-A1 | SAPONIN NANO MICELLE, PREPARING METHOD, APPLICATION AND PHARMACEUTICAL COMPOSITION THEREOF | FUJIAN SOUTH PHARMACEUTICAL CO., LTD. (CN) | 2015-10-22 | — | — | US | disclosed |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8163703-B2 | Hepatitis C therapies | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8133870-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133870-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100143300-A1 | HEPATITIS C THERAPIES | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-06-10 | — | — | US | disclosed |
| US-7514410-B2 | Hepatitis C therapies | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7429571-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | DPYD, TYMP, TYMS | L3MBTL1 3450/4885LGALS1 2623/4885LGALS3 2773/4885 |
| US-10660911-B2 | Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria | ATP5ME, ATP6V1E1, ATF4 | L3MBTL1 3231/4885LGALS1 3884/4885LGALS3 4285/4885 |
| US-11382883-B2 | Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections | HAMP, TIMM50, ATF4 | L3MBTL1 2404/4885LGALS1 3953/4885LGALS3 4196/4885 |
| US-11692004-B2 | Substituted pyrazole compound, preparation method therefor, pharmaceutical composition and medical use thereof | FARS2, GOT2, HADHB | L3MBTL1 1066/4885LGALS1 2980/4885LGALS3 3209/4885 |
| US-10434085-B2 | Non-aromatic difluoro analogues of resorcylic acid lactones | FRS2, FGFR3, FDPS | L3MBTL1 2194/4885LGALS1 3616/4885LGALS3 3398/4885 |
| US-20150297727-A1 | SAPONIN NANO MICELLE, PREPARING METHOD, APPLICATION AND PHARMACEUTICAL COMPOSITION THEREOF | NR1H3, NR1H2, NPC1L1 | L3MBTL1 3006/4885LGALS1 1569/4885LGALS3 2515/4885 |
| US-20180153854-A1 | NON-AROMATIC DIFLUORO ANALOGUES OF RESORCYLIC ACID LACTONES | FRS2, FGFR3, FDPS | L3MBTL1 2194/4885LGALS1 3616/4885LGALS3 3398/4885 |
| US-10632099-B2 | Non-aromatic difluoro analogues of resorcylic acid lactones | FRS2, FGFR3, FDPS | L3MBTL1 2194/4885LGALS1 3616/4885LGALS3 3398/4885 |
| US-20170172920-A1 | LIPOSOMES WITH GINSENOSIDE AS MEMBRANE MATERIAL AND PREPARATIONS AND USE THEREOF | SGMS1, LIPA, SGMS2 | L3MBTL1 4447/4885LGALS1 843/4885LGALS3 1088/4885 |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | DPYD, TYMP, TYMS | L3MBTL1 3450/4885LGALS1 2623/4885LGALS3 2773/4885 |
| US-20100143300-A1 | HEPATITIS C THERAPIES | HAVCR2, FABP1, LIPC | L3MBTL1 3091/4885LGALS1 90/4885LGALS3 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.